[USA] ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products is proud to announce the launch of IMMULINA™ to their family of branded ingredients. The addition brings the total number of ChromaDex patented and proprietary ingredients to six.
IMMULINA™ is a spirulina extract that has demonstrated an ability to enhance the immune response. ChromaDex’s IMMULINA™ has potential as a stand-alone ingredient or as a component in products targeting immune support and sports nutrition.
Frank Jaksch Jr., founder and CEO of ChromaDex, commented, “We are excited to add IMMULINA™ as one of our proprietary branded ingredients. There is a very large existing market for immune support products and we believe IMMULINA™ has compelling, differentiated properties that will make it appealing for inclusion in consumer products.”
ChromaDex has licensed exclusive worldwide rights from the University of Mississippi for several patents related to the isolation and use of immunostimulatory extracts from microalgae. The exclusive worldwide licenses are for U.S. Patent numbers 7,205,284 and 7,846,452.
The licensed technology covers patented and proprietary preparations from food-grade microalgae that are rich in compounds that activate immune cells. The predominant active compounds, Braun-type lipoproteins, are potentially useful for improving human immune function. These lipoproteins within Spirulina platensis, Haematococcus pluvialis, Chlorella pyrenoidosa and Aphanizomenon flos-aquae are present at much greater levels than those found within commonly used immune enhancing botanicals, such as Echinacea and ginseng.
Separately, ChromaDex is also proud to announce that Dr. Loges, a German based company with sales throughout Europe, has launched Immunloges® which features IMMULINA™ as the main ingredient. The unique formula addresses immune activity and response.